Gold Daniel Allen

Director Gold Daniel Allen sells 1,225,784 shares for $32,658,518.16 at Roivant Sciences (ROIV) over 3 days.

Director Gold Daniel Allen executed 5 separate sales totaling 1,225,784 shares for $32,658,518.16 between February 11–13, 2026, at a blended average price of $26.64—near the 52-week high of $27.67. Post-transaction holdings of 15,127,329 shares represent a 7.5% reduction in position. The sale occurs in a company with material operational headwinds: annual revenue declined 76.7% and quarterly revenue is $1,999,000.00 with a net loss of $-265,891,000.00 (full-year unprofitable). His prior five trades at ROIV (all December 2025 sales) showed mixed 30-day returns (+0.4% to +1.6%), with no measurable 90-day outcomes yet. His cross-ticker track record across 20 prior sales shows an average 90-day return of +1.3% and a 0.00% well-timed rate, indicating his prior sales have generally not preceded declines. The high-price timing and large dollar volume ($32.7M) combined with deteriorating fundamentals merit close monitoring of subsequent quarterly results and insider activity patterns.

ROIV Director Gold Daniel Allen sold 1,694,614 shares (1.69M) for $39,065,213.44 across 5 transactions Dec 16-17 at blended avg $23.05

Director Gold Daniel Allen executed 5 separate sales of 1,694,614 shares (1.69M shares) for $39,065,213.44 at a blended average price of $23.05 on December 16–17, reducing his holdings by 9.4% to 16,353,113 shares. The transaction was executed near the 52-week high of $22.94, with current price at $21.79 suggesting a -5.0% pullback has already occurred post-transaction. Against his cross-ticker track record showing a 0.00% well-timed rate on 16 prior sells, this large disposition occurs against a deteriorating fundamental backdrop: the company reported quarterly revenue of $1,571,000.00 with net income of $-113,519,000.00 and annual revenue contraction of -76.7%, while remaining unprofitable. The scale and timing of this multi-transaction disposition warrant investor scrutiny in the context of the company's operational stress.

Director Daniel Allen sold 1,300,000 shares at $20.23 avg for $26.3M, reducing stake by 6.7% at near 52-week highs

Gold Daniel Allen, a director at Roivant Sciences, executed 4 separate sales totaling 1,300,000 shares for $26,304,500.00 on 2025-11-19, reducing his holdings from 19,347,727 to 18,047,727 shares. The blended average price of $20.23 sits within 5.2% of the 52-week high of $21.32 and reflects the stock's strong 30-day performance of +12.6% and 90-day surge of +69.6%. His prior five sales at ROIV all posted positive 90-day returns (ranging +0.8% to +3.0%), indicating a consistent pattern where shares sold subsequently appreciated rather than declined—a signal that his historical exit timing at this ticker has not preceded downturns. The company operates under significant headwinds: latest quarterly revenue of $1,571,000.00, annual revenue contraction of -76.7%, and a full-year net loss of $-113,519,000.00. The sale at elevated valuations amid deteriorating fundamentals represents a material disposition of ownership during a period of exceptional price momentum.

Director Gold Daniel Allen sells 4,426,000 shares for $51.8M over 3 days at avg $11.71; retains 22.18M shares.

Director Gold Daniel Allen executed 6 separate sales totaling 4,426,000 shares for $51,820,727.30 between 2024-09-24 and 2024-09-26 at prices ranging from $11.62 to $11.82 (blended average $11.71). This represents a -16.6% reduction from his pre-transaction holdings of 26,605,358 shares, leaving him with 22,179,358 shares post-transaction. The sales occurred while the stock was trading -12.3% below its 52-week high of $13.19. His prior 5 trades at ROIV, all executed on 2023-09-28, posted a combined 90-day return of +0.3%, with 0 of 5 reaching well-timed status (negative 90-day return after a sell), suggesting his prior ROIV sales did not precede declines. Given ROIV's fundamentals (revenue $55,132,000.00, net income $95,297,000.00, P/E 1.81, market cap $8.6B), this large liquidation warrants investor attention to understand any strategic or personal circumstances driving the disposition, particularly given the magnitude relative to the director's remaining stake.